Aevi Genomic Medicine LLC

Aevi Genomic Medicine — Medgenics — FY2015 Earnings Presentation

38 slides from Aevi Genomic Medicine's earnings presentation, Feb 17, 2016

  1. Slide 1: 2015 Year End Results and Operations Update

    2015 Year End Results and Operations Update February 17, 2016

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, including statements with respect to anticipated operating and financial performance, clinical results

  3. Slide 3: Agenda

    Agenda 3 • 2015 Recap • Business Model Update • NFC - 1 Program Update • Q4/Year - End Results of Operations • 2016 Milestones • Summary

  4. Slide 4: 2015: Pivot Toward Genomic Medicine

    2015: Pivot Toward Genomic Medicine 4 • Acquired lead CNS compound: NFC - 1 – First program from the genomic medicine collaboration with CHOP – Poised to begin multiple CNS clinical trials (mGluR+ ADHD and 22q11.2 Deletion Syndrome ) in H1 2016 • Strengthened company’s balance sheet – Completed fund

  5. Slide 5: Medgenics Vision

    Medgenics Vision 5 Driven by our commitment to patients we strive to create the premier rare and orphan disease company by : – Developing first - to - market or best - in - class therapies that are transformative to patients suffering from life altering rare genetic diseases – Having unparalleled un

  6. Slide 6: Medgenics/CHOP Collaboration

    Medgenics/CHOP Collaboration 6 • Medgenics has an exclusive option to the genomic discoveries made by the Center for Applied Genomics (CAG) in Rare and Orphan diseases • CAG is prolific in discovering novel genetic causes of disease …however... translating discoveries into therapies has been a chall

  7. Slide 7: CAG/CHOP Capabilities

    CAG/CHOP Capabilities 7 Datasets (Genomics EMR) ▪ Over 60K pediatric and 150K related adult patients GWAS genotyped with associated longitudinal EMR since 2006 Data Analytics ▪ End to end internal Next - Gen sequencing capabilities ▪ Integrated bioinformatics ▪ Rapid identification of novel genetic

  8. Slide 8: MDGN/CAG Drug Development Strategy

    MDGN/CAG Drug Development Strategy • Novel targets are validated, and then a search begins for an existing molecule with the correct MOA that can be repurposed – An ideal program will be clinical stage with an excellent safety profile and a suboptimal efficacy signal based on studying heterogeneous

  9. Slide 9: Benefits of Genomic Guided Drug Development

    Benefits of Genomic Guided Drug Development Higher Value Medicines Improved response rates Smaller, faster, clinical trials Increased probability of regulatory success Targeted launch Potential label expansion in adjacent genetic diseases G enomic biomarkers improve overall program outcomes 9

  10. Slide 10: Business Model Evolution: Gene Therapy to Genomic Medicine

    Business Model Evolution: Gene Therapy to Genomic Medicine 10 Diverse Limited Medgenics capabilities Ex vivo Gene Therapy • TARGT Platform Time Genomic Medicine • C ommercial capabilities • Further pipeline diversification Genomic Drug Development • World - class biobank and analytics • G enetically

  11. Slide 11: NFC-1 Summary

    NFC - 1 Summary • First program from the CHOP collaboration – Phase 2/3 ready program via neuroFix acquisition • Program in mGluR+ ADHD is highly de - risked – Extensive safety database – Compelling Phase 1b efficacy signal in mGluR+ ADHD • Potential rapid path to approval in 22q11.2 DS – L arge orp

  12. Slide 12: Non-interventional mGluR+ ADHD Trial

    Non - interventional mGluR + ADHD Trial Phenotype/Genotype Study • Objectives: - Genotype 1,000 ADHD subjects aged 6 - 17 to identify patients who are mGluR+ – Confirm the 20 - 30% prevalence estimate of mGluR + – E xpedite enrollment in Phase 2/3 interventional trial and subsequent trials • Investi

  13. Slide 13: Phase 2/3 Trial of NFC-1 in mGluR+ ADHD

    Phase 2/3 Trial of NFC - 1 in mGluR+ ADHD • Objective: Identify optimal dose of NFC - 1 and confirm enhanced response in mGluR+ patients – Primary endpoints: ADHD RS, CGI - I – Powered to serve as a pivotal trial – Top - line data anticipated H216 • Additional study for approval: – Confirmatory Phas

  14. Slide 14: ADHD Market Opportunity

    ADHD Market Opportunity Overall US Market • 2015 Sales in excess of $10B* (> 60M total prescriptions**) • Approximately 6M pediatric patients • Stimulants dominate market with 90+% of total prescriptions NFC - 1 Opportunity • Genetic Biomarker identifies eligible patients ( approx 20% of all ADHD) a

  15. Slide 15: 22q11.2 Deletion Syndrome Phase 1/2 study

    22q11.2 Deletion Syndrome Phase 1/2 indication & dose finding study • IND clearance received in January 2016 • Study will explore major neuropsychiatric disorders: ADHD, Anxiety, ASD • Initial data expected mid - 2016 • Transition to pivotal trial in one or more disorders • Rapid path to approval ba

  16. Slide 16: Q4 2015 - Results of Operations

    Q4 2015 - Results of Operations • Net R&D expenses for the 4 th Quarter were $4.3MM increasing from $3.8MM for the same period in 2014 due to increased spending to support clinical activities for the NFC - 1 programs and the CHOP collaboration • G&A expenses for the 4 th Quarter were $2.1MM decreasi

  17. Slide 17: NFC-1 Near-term Milestones

    NFC - 1 Near - term Milestones 17 PROGRAM TIMING 22q11.2 Deletion Syndrome (NFC - 1) IND for 22q11.2 DS accepted ✔ Initiate exploratory study of psychiatric symptoms Q1 16 Initial NFC - 1 data readout Mid 16 mGluR+ ADHD (NFC - 1) Initiate Phase 2/3 non - interventional study ✔ Initial Phase 2/3 inte

  18. Slide 18: Summary

    Summary • Transformative year for the Company – Clinical trials with NFC - 1 will initiate in 2016 – Anticipate critical data available in Q3 (22q) and Q4 (mGluR+ ADHD) • Anticipate significant acceleration of Company’s transition to genomic medicine • Potential for additional deals originating from

  19. Slide 19: Appendix

    Appendix 19 medgenics

  20. Slide 20: CAG Breakthrough Discovery

    Elia, Glessner et al. Nature Genetic s, 2012 CAG Breakthrough Discovery 20 Research by Dr. Hakonarson indicated approximately 20% of ADHD patients have an underlying mGluR network mutations • 10 fold increased frequency of copy number variations (CNV ) in the mGluR gene network detected in ADHD popu

  21. Slide 21: NFC-1, first-in-class mGluR Neuromodulator

    NFC - 1, first - in - class mGluR Neuromodulator 21 • Small molecule, non - stimulant agonist of multiple mGluRs : • 1, 3, 5, 7, 8 • Up - regulates GABA B receptors • Positive effects seen in animal models • Ameliorate cognitive impairment • Reduce hyperactivity • Enhance memory • Antipsychotic acti

  22. Slide 22: NFC-1, An Excellent Candidate for Repositioning

    NFC - 1, An Excellent Candidate for R epositioning 22 • Failed on efficacy measure • Excellent safety profile in >1,000 patients • No addiction potential • Excellent oral bioavailability and predictable PK – Twice - daily dosing NFC - 1 tested in a large scale clinical trial in Vascular Dementia pat

  23. Slide 23: NFC-1 GREAT Study: Design and Execution

    NFC - 1 GREAT Study: Design and Execution • Part 1: Single Ascending Dose(SAD)/Pharmacokinetics(PK) – SAD 24 hour PK 50 - 800mg • Part 2 : Ascending Dose Trial – 1 week of placebo followed by 4 weeks active therapy – Dose escalated: 50mg BID* - 400mg BID* weekly (x4) – Efficacy endpoints CGI, Vander

  24. Slide 24: GREAT Study Enrolled Complex, Severe Patients

    GREAT Study Enrolled Complex, Severe Patients Inclusion Criteria • ADHD patients age 12 – 17 • mGluR network mutation positive ( mGluR +) Severe ADHD symptoms and high comorbidity • 73% had severe ADHD (CGI - S >5 at baseline) • 67% had co - morbid psychiatric conditions – Anxiety, ODD – 30% on anti

  25. Slide 25: Strong Efficacy Signal in Key Endpoints

    25 Response rates for both scales (CGI - I and Vanderbilt Parent Rating Scale) approx 80% Strong Efficacy Signal in Key Endpoints Treatment effect appeared more robust over time and at higher doses CGI - I, Clinical Global Impression of Symptom Improvement Responder – Global rating of much or very m

  26. Slide 26: Proportion of Responders (Vanderbilt)

    26 Proportion of Responders (Vanderbilt) Note: Data is for the subset of patients who titrated to the highest dose (N=18). Genetic tiers were not balanced. Vanderbilt - Proportion of Responders at Week 5 by Genetic Tier ( with 95% confidence intervals) Core Mutations (Tier1/2) Predict Higher Respons

  27. Slide 27: Statistically Significant Improvement in Key Endpoints

    Statistically Significant Improvement in Key Endpoints 27 Week 1 Week 2 Week 3 Week 4 Week 5 Mean 29.1 26.4 24.0 23.3 22.5 Week 1 Week 2 Week 3 Week 4 Week 5 Mean 3.79 3.13 2.79 2.79 2.21 P < 0.001 P < 0.001 Average Vanderbilt score at each week – all patients Average CGI - I score at the end of eac

  28. Slide 28: mGluR Network Mutation Classification: Genetic Tiers

    28 mGluR Network Mutation Classification: “Genetic Tiers” Tier 3 • 800+ Genes • 30% of ADHD Tier 2 • 279 Genes • 20% of ADHD Tier 1 • 79 Genes • 10% of ADHD Tier 1 Mutations in genes in mGluR receptors or that directly influence mGluR signaling. n=17 Tier 2 Mutations in genes that encode proteins th

  29. Slide 29: NFC-1 GREAT Trial Study Summary

    NFC - 1, GREAT Trial Study Summary • Strong efficacy signal in several validated ADHD scales • Improvement magnitude comparable to best in class drugs in complex, severe patients • Improvement in multiple symptoms noted by caregivers – I nattention, hyperactivity, anxiety, mood disorders • Treatment

  30. Slide 30: 22q11.2 Deletion Syndrome (DS) Overview

    22q11.2 Deletion Syndrome (DS) Overview 30

  31. Slide 31: Orphan Opportunity - 22q11.2 DS

    Orphan Opportunity - 22q11.2 DS • 90% of 22q11.2DS patients have at least one mGluR network related deletion (RANBP1) 31 Micro deletion occurs in chromosome 22 Hypothesis: neuropsychiatric symptoms in 22q11.2DS patients are causally related to mGluR CNV/mutations and will respond to NFC - 1

  32. Slide 32: Orphan Opportunity - 22q11.2 DS Symptoms

    32 Orphan Opportunity - 22q11.2 DS Physical Symptoms • Heart defects • Cleft palate • Gastrointestinal problems • Poor wound healing • Skeletal abnormalities Surgical / medical therapies mortality <4% after CV surgery (excluding critically ill infants) No effective therapy Approx. 40% progress to sc

  33. Slide 33: 22q11.2 Patient in GREAT Study

    22q11.2 Patient in GREAT Study 33 T wo 22q11.2 p atients in the trial; one deletion and one duplication • Parents reported significant symptom improvement in both • M arked improvement in CGI - I and Vanderbilt • Both families elected to enroll in long - term safety trial to maintain access to NFC -

  34. Slide 34: Opportunity to work with the Leading 22q11.2 Center

    Opportunity to work with the Leading 22q11.2 Center • “ 22q and You” Center at The Children’s Hospital of Philadelphia (CHOP) – World’s leading 22q11.2 Deletion Syndrome (DS) Center – Caring for > 1,300 children with a 22q11.2 deletion – Draws families from around the world – Staffed by geneticists,

  35. Slide 35: TARGT – Ex vivo Gene Therapy

    TARGT – Ex vivo Gene Therapy 35

  36. Slide 36: TARGT EPO

    TARGT EPO • Trial Status – Completed enrollment in low - dose, mid - dose and PD cohorts • High dose cohort was not needed • Safe and well - tolerated; no treatment related SAE • 9/13 patients were EPO and transfusion free for at least 5 months • One patient maintains stable EPO production and Hb re

  37. Slide 37: Stanford GeneRide Technology

    Stanford GeneRide Technology • Novel technology for highly specific and permanent integrated genetic transduction without lentivirus • Based on “promoter - less” homologous recombination – AAV - based – Permanent – Specific and controlled integration: no “off target” integration – Uses natural promo

  38. Slide 38: TARGT CNS

    TARGT CNS – Goal : sustained autologous large molecule production in central nervous system (CNS) – Future disease targets: • M etastatic and primary brain tumors • Lysosomal storage diseases with CNS involvement – Preclinical POC and IND - enabling work underway – First IND filing expected in 2017

Medgenics — FY2015 Earnings Presentation on 6ix